WO2020111674A1 - Composition contenant des bactéries lactiques dérivées de thé vert pour le soin de la perte des cheveux provoquée par de la poussière fine - Google Patents

Composition contenant des bactéries lactiques dérivées de thé vert pour le soin de la perte des cheveux provoquée par de la poussière fine Download PDF

Info

Publication number
WO2020111674A1
WO2020111674A1 PCT/KR2019/016163 KR2019016163W WO2020111674A1 WO 2020111674 A1 WO2020111674 A1 WO 2020111674A1 KR 2019016163 W KR2019016163 W KR 2019016163W WO 2020111674 A1 WO2020111674 A1 WO 2020111674A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
lactic acid
fine dust
acid bacteria
green tea
Prior art date
Application number
PCT/KR2019/016163
Other languages
English (en)
Korean (ko)
Inventor
신승현
김수나
명길선
나용주
Original Assignee
㈜아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ㈜아모레퍼시픽 filed Critical ㈜아모레퍼시픽
Publication of WO2020111674A1 publication Critical patent/WO2020111674A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • compositions for treating skin cell damage caused by fine dust More specifically, a composition comprising lactic acid bacteria derived from green tea is disclosed to significantly treat skin cell damage by significantly changing a biomarker, which is a skin cell gene whose expression level is changed by fine dust, compared to normal skin cells. .
  • Fine dust is more harmful to the human body because it has a smaller size particle than ordinary yellow sand, and is more permeable to the human body and contains more harmful substances such as heavy metals, nitrates, ammonium, and sulfates.
  • cells responsible for the body's immunity act to remove dust.
  • the World Health Organization classifies fine dust as a group of carcinogens directly related to cancer.
  • Fine dust is expected to penetrate into the skin and hair follicles as well as the respiratory tract and cause skin trouble or hair loss, but the mechanism and target studies on how to negatively affect the skin and hair are only incomplete, solving problems accordingly Research on anti-pollution materials to do not have been conducted.
  • Non-Patent Document 1 discloses that the expression level of claudin 1 (CLDN 1), a major component of the tight junction, which is a granular layer barrier, was decreased due to the fine dust stimulation of PM 2.5.
  • CLDN 1 claudin 1
  • lactic acid bacteria refers to bacteria that break down sugars such as glucose to produce lactic acid, and is also called lactic acid bacteria. Lactic acid produced by lactic acid fermentation of lactic acid bacteria can inhibit the growth of pathogens and harmful bacteria, and these properties are used in the manufacture of foods such as dairy products, kimchi, and brewed foods. In addition, lactic acid bacteria inhabit the intestines of mammals to prevent abnormal fermentation by germs, which is an important bacterium used as a dressing agent.
  • Lactobacillus plantarum ( Lactobacillus plantarum ) is a strain belonging to lactic acid bacteria and is known to grow mainly when sour fermentation of kimchi is carried out and sour.
  • the optical isomers of lactic acid produced are D-type and L-type. Since Lactobacillus plantarum can be widely used in various foods that require fermentation, it is known about Lactobacillus plantarum having excellent acid resistance, bile acid resistance, and antibacterial activity, but has the effect of strengthening the skin barrier and damaging skin cells. It is not known as an anti-pollution material, such as the efficacy of restoring.
  • Non-Patent Document 1 Kim, HJ, et al, "Transcriptome analysis of airborne PM 2.5 -induced detrimental effects on human keratinocytes", Toxicology Letters 273, 26-35, 2017.
  • the present inventors have a fine dust having a detrimental effect on the hair follicles, and these effects also affect the expression of the hair follicle cell gene in the hair follicle, resulting in symptoms such as hair cell damage, and the effect of green tea-derived lactic acid bacteria to restore the expression of the gene. It was confirmed that there is.
  • the present invention aims to provide a composition for the care of damage to hair follicles by fine dust comprising green tea-derived lactic acid bacteria, its crushed product, its culture, its dead body, or its extract.
  • the present invention is a composition
  • a composition comprising lactic acid bacteria derived from green tea, its lysate, its culture, its dead body, or its extract as an active ingredient, and the expression level is affected by fine dust.
  • a composition for hair loss care by fine dust that regulates the expression level of claudin 1 (CLDN 1), a gene in a receiving follicle, to a normal level.
  • the amount of gene expression changed by fine dust can be returned to a normal level to care for damage to hair follicle cells in hair follicles.
  • Figure 1 shows a qPCR result showing the change in the mRNA expression level of the claudin 1 (CLDN 1) gene, when treating the reference strain (type strain) or green tea-derived lactic acid bacteria according to an embodiment of the present invention in hair follicle outer root sheath cells .
  • CLDN 1 claudin 1
  • Figure 2 is a graph showing the average value of each hair follicle growth length for each measured date after treatment with a reference strain (type strain) or lactic acid bacteria derived from green tea according to an embodiment of the present invention.
  • the composition for hair loss care by the fine dust may include green tea-derived lactic acid bacteria, its lysate, its culture, its dead body, or its extract as an active ingredient.
  • green tea-derived lactic acid bacteria may mean lactic acid bacteria isolated from tea tree leaves, tea tree flowers, tea tree trunks, tea tree roots, or nearby soil.
  • it may mean lactic acid bacteria cultured and separated from green tea, which is a tea tree leaf.
  • strain strain may mean a product obtained by crushing the strain itself by chemical or physical force.
  • culture may mean a substance including all substances contained in a culture medium of a strain, for example, a substance containing metabolites or secretions that are the result of strain culture or a fragment thereof.
  • the strain itself may also be included in the culture.
  • extract may mean a product obtained by extracting a strain itself, a crushed product of a strain, its culture, its dead body, or a mixture thereof using an extraction solvent.
  • Green tea lactic acid bacteria according to an embodiment of the present invention is a separation of lactic acid bacteria among the various components contained in the leaves of the tea tree, when applied to the skin damaged by fine dust, specifically when applied to a tight junction in the hair follicle (tight junction)
  • the efficacy of repairing damaged hair follicles, such as hair follicle structure, can be very good.
  • the tea-derived lactic acid bacteria may be lactic acid bacteria Lactobacillus genus (Lactobacillus sp.). Specifically, the lactic acid bacteria derived from green tea may be Lactobacillus plantarum . More specifically, the green tea derived lactic acid bacteria may be Lactobacillus plantarum APsulloc 331266 ( Lactobacillus plantarum APsulloc 331266) KCCM11181P.
  • the green tea-derived lactic acid bacteria can strengthen the tight junction of the hair follicles, and in particular, the Lactobacillus plantarum APsulloc 331266 ( Lactobacillus plantarum APsulloc 331266) KCCM11181P may have an effect of restoring the damaged hair follicle structure by fine dust. .
  • the composition may include green tea-derived lactic acid bacteria, its lysate, its culture, its dead body, or its extract in an amount of 0.000001 to 30% by weight based on the total weight of the composition. .
  • the content is less than 0.000001, the effect of preventing hair loss may be insignificant, and when it is more than 30% by weight, the efficiency of hair loss care by fine dust may be reduced.
  • the active ingredient of the composition according to the invention may be to act on a tight junction in the hair follicle. Specifically, it may act as a barrier by acting in close contact with the hair follicle and may maintain the structure of the hair follicle.
  • Tight junction is a kind of cell junction, and consists of occluding, claudin, tricellulin, junctional adhesion molecule (JAM), and zona occluden (ZO).
  • the adhesion junction can be divided into a part contained in a cell membrane and an intracellular part, of which Occludin and claudin are close junction construct proteins contained in the cell membrane.
  • Occludin is the first transmembrane protein found in close junctions, has four transmembrane regions, and is known to regulate the function of close junctions as well as the components of close junctions.
  • claudin which is a close junction protein with Occludin, also has four transmembrane regions.
  • the close junction is a link between cells, which fills the gap between neighboring cells and cells, regulates the movement of small substances, and also plays a role in regulating the permeation of substances between cells and maintaining the polarity of cells. Recently, it has been reported through research results that close contact plays an important role in skin barrier function.
  • a tight junction is a type of intercellular bond, which is a cell-to-cell junction mainly found in epithelial and endothelial cells, and forms a complex network with a string-like structure.
  • the close connection has two functions from this structure. The first is a barrier function, which prevents the leakage of substances between cells constituting epithelial cells or endothelial cells. It is mainly treated in the blood vessels and digestive tract.
  • the second is the fence function, which is a function of partitioning the cell membrane around the string-shaped fence in the cell membrane lipid.
  • the close junction in the hair follicle may be expressed in hair follicle outer root sheath cells (ORS) and act as a barrier. At this time, the close junction may serve to maintain the hair follicle structure as well as the barrier.
  • ORS hair follicle outer root sheath cells
  • the active ingredient of the composition according to the present invention acts in close contact with the hair follicles, thereby enhancing the barrier function and the fence function of the hair root cells to care for hair loss caused by stimulation of fine dust.
  • Another aspect of the present invention includes the use of hair loss care by fine dust of the composition.
  • fine dust refers to a particulate matter that floats or scatters in the air for a long time as a very small material that is invisible to our eyes.
  • the particle size of the fine dust may be 10 ⁇ m or less (PM 10), and specifically 2.5 ⁇ m or less (PM 2.5).
  • particulate matter having a particle diameter of 2.5 ⁇ m (PM 2.5) or less is referred to as “ultrafine dust”, and “fine dust” is intended to include “ultrafine dust” herein.
  • the fine dust in the present invention may include one or more of arsenic, cadmium, lead, and nickel.
  • Heavy metal components such as arsenic, cadmium, lead, and nickel are included in fine dust to attack hair follicle cells, etc., causing skin allergies, pigmentation, inflammation, and skin aging. Can cause.
  • the fine dust includes arsenic, cadmium, lead, and nickel.
  • the term “care” means to effectively protect the hair follicle structure from external stimuli such as fine dust, and to suppress, prevent, and repair (restore) the change in the expression level of a specific gene due to the stimulation. do.
  • “recovery” also includes improving the expression level above the reference level, in addition to changing the expression level close to the reference level, based on the gene expression level in the absence of stimulation.
  • the method requires an effective amount of green tea-derived lactic acid bacteria, its lysate, its culture, its dead body, or its extract It provides a method comprising the step of administering to.
  • In one aspect of the present invention provides a use of green tea-derived lactic acid bacteria, its lysate, its culture, its mortality, or its extract in preparing a composition for preventing hair loss by fine dust.
  • In one aspect of the present invention provides a green tea-derived lactic acid bacteria, its lysate, its culture, its dead body, or its extract for preventing hair loss by fine dust.
  • the present invention provides a composition for inhibiting and preventing hair loss caused by fine dust by controlling the expression level of a specific gene in skin cells damaged by fine dust to a normal level.
  • a gene in skin cells whose expression level is affected by fine dust may include claudin 1 (CLDN 1).
  • CLDN 1 is a gene whose expression level decreases due to fine dust, and thus it is possible to suppress damage to skin cells by increasing the expression level of these genes and regulating them to normal levels.
  • composition according to the present invention can alleviate and/or restore human hair follicle growth inhibition by fine dust.
  • Analysis of the expression level of the gene or protein is microarray, PCR, NGS (Nest Generation Sequencing), Western blot, Northern blot, ELISA, radioimmunoassay, radioimmunoassay, tissue immunostaining, immunoprecipitation assay, etc. It can be analyzed using a variety of analytical methods known in the art.
  • damage to hair follicle cells may occur due to fine dust, and in this case, inflammation may be induced to further damage hair follicle cells. It is possible to prevent hair loss by treating the vicious cycle of skin cell damage by lactic acid bacteria derived from green tea.
  • the composition may be a cosmetic composition, may be a pharmaceutical composition, may be a health functional food composition.
  • the cosmetic composition includes, for example, various creams, lotions, various creams, lotions, skins, and cosmetics such as cleansing, face wash, soap, and cosmetic liquid.
  • the cosmetic composition to which the composition containing the green tea-derived lactic acid bacteria of the present invention is added may take the form of a solution, an emulsion, a viscous mixture, and the like.
  • the cosmetic composition of the present invention is not particularly limited in its formulation, for example, emulsion, cream, lotion, essence, pack, gel, powder, makeup base, foundation, lotion, ointment, patch, cosmetic liquid, cleansing And formulations such as foam, cleansing cream, cleansing water, body lotion, body cream, body oil, body essence, shampoo, conditioner, body cleaner, soap, hair dye, and spray.
  • the cosmetic composition of the present invention may include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingo lipids, and seaweed extract.
  • the cosmetic composition of the present invention may be blended with the essential ingredients as well as other ingredients that are usually blended into the cosmetic composition as necessary.
  • ingredients that may be added include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavors, And blood circulation accelerators, cooling agents, limiting agents, and purified water.
  • the compounding component which may be added in addition is not limited to this, and any of the above components can be compounded within a range not impairing the object and effect of the present invention.
  • the pharmaceutical composition comprising lactic acid bacteria derived from green tea of the present invention may further include a suitable carrier, excipient and diluent commonly used in the manufacture of pharmaceutical compositions.
  • the pharmaceutical composition containing the green tea-derived lactic acid bacteria may include oral preparations such as tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays, according to a conventional method, respectively. It can be formulated and used in any form suitable for pharmaceutical preparations.
  • the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in light of various related factors such as severity of symptoms, selected route of administration, age, sex, weight and health status of the subject.
  • the dosage of the active ingredient may be 0.0001 mg/kg/day to 3000 mg/kg/day, for example, 10 mg/kg/day to 500 mg/kg/day.
  • the health food is manufactured using raw materials or ingredients (functional ingredients) having nutrients or functions useful for the human body that are easily deficient in everyday meals, and maintains normal functions of the human body. Or it may mean food that maintains and improves health through activation of physiological functions, but is not limited thereto.
  • the health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., but is not limited thereto and may be manufactured and processed in any form according to law.
  • the healthy beverage composition has no particular limitation on other components except for containing the compound as an essential component in the indicated proportions, and may contain various flavoring agents or natural carbohydrates, etc., as additional components, as in conventional beverages.
  • natural carbohydrates are conventional sugars such as monosaccharide polysaccharide, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • flavoring agents other than those described above natural flavoring agents (taumatine, stevia extract (for example, rebaudioside A, glycyrrhizine, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
  • the actual dosage of the active ingredient administered by the dietary supplement composition should be determined in light of various related factors such as severity of symptoms, selected route of administration, age, sex, weight and health status of the subject. .
  • the dosage of the active ingredient may be 0.0001 mg/kg/day to 1000 mg/kg/day, for example, 0.02 mg/kg/day to 6 mg/kg/day.
  • Lactobacillus Planta Room Lactobacillus plantarum APsulloc Culture and isolation of 331266
  • tea leaves 200 g are washed twice with primary distilled water to remove foreign substances.
  • the washed tea leaves are drained, mixed with a salt equivalent to 8% of the weight of the tea leaves and left at room temperature for 3 hours.
  • the saline leaves are mixed with 1000 mL of 1% fructo-oligosaccharide solution and incubated in a 32°C incubator for 3 days. After 3 days, check if the pH of the culture solution has dropped to less than 5, and if it is less than 5, take it and incubate in Difco Lactobacilli MRS Agar® medium. At this time, the culture was incubated for 2 days in a chamber of 32° C., anaerobic conditions, and colonies showing white colonies were taken.
  • Lactobacillus plantarum APsulloc 331266 Lactobacillusplantarum APsulloc 3312666 was isolated from tea leaves in the same manner as above.
  • the Lactobacillus plantarum APsulloc 331266 Lactobacillus plantarum APsulloc 331266) was deposited on March 28, 2011 with the Korean Culture Center of Microorganisms under the microbial accession number KCCM11181P.
  • Lactobacillus Planta Room Lactobacillusplantarum .
  • Example 1 The APsulloc 331266 isolated in Example 1 was streaked on an MRS agar plate and incubated at 37°C for 2 days. The obtained single colony was inoculated into 10 mL of MRS broth and cultured at 37°C overnight to prepare APsulloc 331266 culture.
  • the APsulloc 331266 strain culture solution prepared as above (1) was inoculated 0.5% in 10 mL of MRS broth and cultured overnight at 37°C.
  • the culture solution was centrifuged at 8,000 rpm for 5 minutes, the supernatant was removed, and only the cells were collected, followed by suspension by adding 2 mL of 0.85% saline buffer. Then, it was performed according to the manufacturer's protocol using the API 50CHL kit (Biomerieux). The details are as follows.
  • Lactobacillus plantarum Lactobacillusplantarum
  • KCTC3108 Lactobacillusplantarum strain as a standard strain compared APsulloc 331266 sugar fermentation pattern results and the results of the identification of APsulloc 331266 using the results are as follows.
  • APsulloc 331266 is a different strain because the standard strain (KCTC3108) and ⁇ -methyl-mannoside and raffinose use properties are different.
  • Lactobacillus plantarum APsulloc 33126 which was identified and isolated, was cultured in a medium (MRS Broth) at 37° C. for 24 hours.
  • MFS Broth a medium
  • the lactic acid bacteria were inoculated with skim milk stored in cryotube at 10% by weight.
  • concentration of bacteria in the liquid medium was 5 X 10 8 ⁇ 1 X 10 9 CFU/mL, at 4°C, trophic cells were harvested through 4000 rpm centrifugation and the cells were washed with PBS (phosphate buffered saline).
  • the washed cells were re-dispersed in PBS at a concentration of 5 X 10 8 ⁇ 1 X 10 9 CFU/mL (resuspension) and heated at 100° C. for 10 minutes to prepare Lactobacillus plantarum dead bodies.
  • Lactobacillus plantarum reference strain (type strain) was used, and a deposit strain of deposit No. KCTC3108 was obtained from the Biological Resource Center and used.
  • Appearance geuncho cells are purchased from the University Gyeongsangbuk passaged and cultured under the culture after a CO 2 incubator (CO 2 incubator) at 37 °C, 5% CO 2 condition.
  • the fine dust used was ERM-CZ120 fine dust commercially available from Sigma-Aldrich, PM 10 level fine dust, arsenic, cadmium, lead, and nickel. It contains.
  • 6-well plates were used and the culture medium of the prepared follicular follicular sheath cells was cultured under the conditions of cell culture conditions 3 ⁇ 10 5 cells/well, untreated (control 1), fine dust as a control, respectively.
  • Group treated with 50 ppm Control 2), 50 ppm of fine dust and Lactobacillus plantarum reference strain (type strain) treated with 1 ⁇ g/ml (Example 2), 50 ppm of fine dust and green tea-derived Lactobacillus plaque
  • Lactobacillus plantarum reference strain (type strain) was obtained from the Biological Resource Center, and a deposit strain of deposit number KCTC3108 was used.
  • ERM -CZ120 Fine Dust Manufacturing example 1 strain ( APsulloc 331266) Manufacturing example 2 strains (type strain) Control 1 (fine dust untreated) - - - Control 2 (fine dust treatment) 50 ppm - - Example 1 (fine dust + Preparation Example 1 (KCCM11181P) treatment) 50 ppm 1 ⁇ g/ml - Example 2 (fine dust + manufacturing example 2 (KCTC3108) treatment) 50 ppm - 1 ⁇ g/ml
  • the prepared control group 1, control group 2, Example 1, and Example 2 were removed from the culture medium, washed with 2 ml of phosphate buffer (Phosphate Buffered Saline, PBS), and then Trizol reagent (Trizol reagent, Invitrogen, Carlsbad, CA, USA) to isolate RNA in cells.
  • phosphate buffer Phosphate Buffered Saline, PBS
  • Trizol reagent Trizol reagent, Invitrogen, Carlsbad, CA, USA
  • RT Superscript Reverse Transcriptase
  • Q-RT-PCR real time-reverse transcription polymerase chain reaction
  • Example 1 it was confirmed that the mRNA expression level of claudin 1 (Claudin 1) was improved to have an effective meaning compared to the control 2 treated with fine dust.
  • Example 2 reference strain
  • the mRNA expression level of claudin 1 was not significantly different from that of the control group 2 treated with fine dust, and thus, the mRNA change amount was significantly significant by treatment with the Lactobacillus plantarum reference strain. It did not have a value, it was confirmed that the reference strain has no effect of restoring the reduced mRNA expression level of the markers.
  • the composition according to the present invention contains green tea-derived lactic acid bacteria (especially KCCM11181P), its lysate, its culture, its dead body, or its extract as an active ingredient, and has an effect of treating hair loss due to fine dust.
  • green tea-derived lactic acid bacteria especially KCCM11181P
  • its lysate especially KCCM11181P
  • its culture especially KCCM11181P
  • its extract as an active ingredient
  • the biopsy tissue of the occipital head for experimental application was collected from the human body and trimmed with a follicular unit to separate 15 hair follicle samples (60 total) per group.
  • the isolated hair follicle sample was placed in a 24 well plate (Nunc, Wiesbaden, Germany) in 2 mM L-glutamine (PAA, Coelbe, Germany), 10 ⁇ g/ml insulin, 10 ng/ml hydrocortisone (Sigma, St Louis, MO).
  • Example 1 green tea-derived lactic acid bacteria
  • Example 2 reference strain
  • the growth of hair follicle length was not significantly different from that of control group 2 treated with fine dust and did not have an effective meaning, and thus the Lactobacillus platarum reference strain was reduced in hair follicles by fine dust. It was confirmed that there was no effect of restoring the decrease in length growth again.
  • the green tea-derived lactic acid bacteria according to the present invention have the effect of treating hair loss caused by fine dust by including the crushed product, its culture, its dead body or its extract as an active ingredient.
  • composition according to the present invention will be described, but the cosmetic composition, the pharmaceutical composition, and the health functional food composition can be applied in various dosage forms, which are not intended to limit the present invention, but only to be described in detail. .
  • tablets were prepared by tableting according to a conventional tablet manufacturing method.
  • the capsules were prepared by filling into gelatin capsules according to a conventional capsule preparation method.
  • Lactobacillus plantarum lactic acid bacteria 50mg, anhydrous crystalline glucose 250mg and starch 550mg according to an embodiment of the present invention were mixed, molded into granules using a fluidized bed granulator, and then filled into the fabric.
  • Lactobacillus plantarum lactic acid bacteria (Example) 5.00 maintain Proper Sodium hydroxide Proper Sodium chloride Proper Spices Proper Purified water Balance
  • Lactobacillus plantarum lactic acid bacteria (Example) 5.00 L-ascorbic acid-2-magnesium phosphate salt 1.00 Water soluble collagen (1% aqueous solution) 1.00 Sodium citrate 0.10 Citric acid 0.05 Licorice extract 0.20 1,3-butylene glycol 3.00 Purified water Balance
  • Lactobacillus plantarum lactic acid bacteria (Example) 3.00 Polyethylene glycol monostearate 2.00 Self-emulsifying monostearate glycerin 5.00 Cetyl alcohol 4.00 Squalene 6.00 Tri2-ethylhexanoate glyceryl 6.00 Sphingolipid lipid 1.00 1.3-butylene glycol 7.00 Purified water Balance
  • Lactobacillus plantarum lactic acid bacteria (Example) 5.00 Polyvinyl alcohol 13.00 L-ascorbic acid-2-magnesium phosphate salt 1.00 Lauroylhydroxyproline 1.00 Water soluble collagen (1% aqueous solution) 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water Balance
  • Lactobacillus plantarum lactic acid bacteria (Example) 3.00 Hydroxyethylene cellulose (2% aqueous solution) 12.00 Xanthan gum (2% aqueous solution) 2.00 1,3-butylene glycol 6.00 Concentrated glycerin 4.00 Sodium hyaluronate (1% aqueous solution) 2.00 Purified water Balance
  • Lactobacillus plantarum lactic acid bacteria (Example) 2mg Vitamin A acetate 70 ⁇ g Vitamin E 1.0mg Vitamin B1 0.13mg Vitamin B2 0.15mg Vitamin B6 0.5mg Vitamin B12 0.2 ⁇ g Vitamin C 10mg Biotin 10 ⁇ g Nicotinamide 1.7mg Folic acid 50 ⁇ g Calcium pantothenate 0.5mg Ferrous sulfate 1.75mg Zinc oxide 0.82mg Magnesium carbonate 25.3mg Potassium Phosphate 15mg Dicalcium phosphate 55mg Potassium citrate 90mg Calcium carbonate 100mg Magnesium chloride 24.8mg
  • Lactobacillus plantarum lactic acid bacteria (Example) 50mg Citric acid 1000mg oligosaccharide 100 g Taurine 1 g Purified water Balance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition pour le soin de la perte de cheveux provoquée par de la poussière fine, la composition contenant comme principe actif des bactéries lactiques dérivées de thé vert, un lysat correspondant, une culture de celles-ci, des corps apoptotiques correspondant ou un extrait correspondant, et permettant d'ajuster à un niveau normal la quantité des produits d'expression de claudine 1 (CLDN 1), qui est un gène exprimé dans les cellules de la racine des cheveux et dont la quantité de produits d'expression est affectée par de la poussière fine. Grâce à l'utilisation de la composition de la présente invention, la quantité des produits d'expression du gène, qui est modifiée par la poussière fine, peut être restaurée à des niveaux normaux, et les cellules endommagées de la racine des cheveux peuvent être soignées.
PCT/KR2019/016163 2018-11-29 2019-11-22 Composition contenant des bactéries lactiques dérivées de thé vert pour le soin de la perte des cheveux provoquée par de la poussière fine WO2020111674A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180150850A KR20200064594A (ko) 2018-11-29 2018-11-29 녹차 유래 유산균을 포함하는 미세먼지에 의한 탈모 케어용 조성물
KR10-2018-0150850 2018-11-29

Publications (1)

Publication Number Publication Date
WO2020111674A1 true WO2020111674A1 (fr) 2020-06-04

Family

ID=70851821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/016163 WO2020111674A1 (fr) 2018-11-29 2019-11-22 Composition contenant des bactéries lactiques dérivées de thé vert pour le soin de la perte des cheveux provoquée par de la poussière fine

Country Status (2)

Country Link
KR (1) KR20200064594A (fr)
WO (1) WO2020111674A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4071236A1 (fr) * 2021-04-06 2022-10-12 Cnce Innovacion, S.L. Probiotique pour le traitement et la prévention de l'alopécie

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102429565B1 (ko) 2021-09-13 2022-08-04 연세대학교 원주산학협력단 락토바실러스 플란타럼 큐원을 유효성분으로 함유하는 탈모 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009141543A1 (fr) * 2008-04-21 2009-11-26 L'oreal Utilisation d'un extrait de baie, et plus particulierement de wolfberry, a titre d'agent anti-pollution
US20140065209A1 (en) * 2011-05-03 2014-03-06 Dupont Nutrition Biosciences Aps Probiotic bacteria for the topical treatment of skin disorders
KR20180034085A (ko) * 2016-09-27 2018-04-04 (주)아모레퍼시픽 락토바실러스 플란타룸의 용출물을 포함하는 모발 또는 두피용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009141543A1 (fr) * 2008-04-21 2009-11-26 L'oreal Utilisation d'un extrait de baie, et plus particulierement de wolfberry, a titre d'agent anti-pollution
US20140065209A1 (en) * 2011-05-03 2014-03-06 Dupont Nutrition Biosciences Aps Probiotic bacteria for the topical treatment of skin disorders
KR20180034085A (ko) * 2016-09-27 2018-04-04 (주)아모레퍼시픽 락토바실러스 플란타룸의 용출물을 포함하는 모발 또는 두피용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R, RAJPUT: "Understanding hair loss due to air pollution and the approach to management", HAIR : THERAPY & TRANSPLANTATION, vol. 5, no. 133, 2015, XP055712292, DOI: 10.4172/21670951.1000133 *
ZORN-KRUPPA, MICHAELA ET AL.: "Tight Junction barriers in human hair follicles-role of claudin-1", SCIENTIFIC REPORTS, vol. 8, 24 August 2018 (2018-08-24), pages 12800, XP055712295 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4071236A1 (fr) * 2021-04-06 2022-10-12 Cnce Innovacion, S.L. Probiotique pour le traitement et la prévention de l'alopécie
WO2022214551A1 (fr) 2021-04-06 2022-10-13 Cnce Innovacion, S.L. Probiotique pour le traitement et la prévention de l'alopécie

Also Published As

Publication number Publication date
KR20200064594A (ko) 2020-06-08

Similar Documents

Publication Publication Date Title
WO2014193014A1 (fr) Bactéries lactiques de taille nanométrique issues du kimchi
US11634685B2 (en) Sporichthyaceae microorganism and use thereof
WO2014069874A1 (fr) Composition permettant d'éliminer des substances kératiniques de la peau comprenant des lactobacillus de thé vert
KR101875001B1 (ko) 락토바실러스 퍼멘툼 gfcsj 균주 및 이를 이용하여 제조된 카카오닙스 발효 추출물
KR101406168B1 (ko) 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물
WO2022080839A1 (fr) Composition antioxydante, anti-inflammatoire et de blanchiment comprenant des bactéries d'acide lactique dérivées de la peau
WO2019143055A1 (fr) Composition comprenant un extrait de haricots fermentés obtenu à partir d'une fermentation par une souche d'aspergillus fumigatus, pour l'amélioration de soins cutanés
WO2020111674A1 (fr) Composition contenant des bactéries lactiques dérivées de thé vert pour le soin de la perte des cheveux provoquée par de la poussière fine
WO2019098808A2 (fr) Composition destinée à améliorer les lésions cutanées provoquées par la micropoussière et comprenant une culture ou un extrait de souche d'aureobasidium pullulans
WO2019088421A1 (fr) Composition pour le traitement de lésions de cellules cutanées provoquées par les poussières fines, contenant des bactéries lactiques dérivées du thé vert
KR102485257B1 (ko) 동백 유래 유산균을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
CN110872568B (zh) 包括短小芽孢杆菌菌株或其培养液的用于预防或改善老化的组合物
KR101508717B1 (ko) 누에 유래 혈림프를 포함하는 화장료 조성물
KR20160084822A (ko) 장내환경개선효과를 갖는 나노형 김치 유산균 조성물
KR20130105309A (ko) 세포 보호제
WO2019078463A1 (fr) Composition pour traiter les lésions des cellules de la peau provoquées par la poussière fine, comprenant un extrait de thé vert
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière
KR20140048911A (ko) 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물
WO2012015242A2 (fr) Nouvelle composition antimicrobienne, et son procédé de préparation
WO2019059527A1 (fr) Composition pour traiter des lésions cutanées provoquées par une poussière fine, comprenant un extrait de fleur de prunus mume
TWI843023B (zh) 新型乳桿菌屬菌株及其用途
WO2021006464A1 (fr) Nouvelle souche de paenisporosarcina quisquiliarum 17mud 1-1541 et son utilisation
WO2022045638A1 (fr) Composition destinée à améliorer l'état de la peau contenant, en tant que principe actif, un extrait de nid de pétrel-tempête fermenté à l'aide d'une nouvelle souche du genre lactobacillus
WO2023234698A1 (fr) Composition d'amélioration de la peau contenant un exosome dérivé d'armoise en tant que principe actif
US20220168370A1 (en) Elastase activity inhibitor, elastase activity inhibiting topical agent, and elastase activity inhibiting food and beverage composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19888958

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19888958

Country of ref document: EP

Kind code of ref document: A1